National Stock Number
6505-01-265-6313
National Stock Number (NSN) 6505-01-265-6313, or NIIN 012656313, (iopamidol injection) was assigned October 17, 1987 in the Federal Logistics Information System (FLIS). This NIIN is Available for Manual Assignment. This NSN does not replace any other NSNs.
There is only one manufacturer part number associated with this NSN. One of those part number(s) are considered obsolete. The manufacturer part numbers were originally supplied by 2 suppliers. Today, one supplier is listed as an Active supplier for this NSN. Of the active suppliers, only one supplier is deemed design controlled or valid supply parts.
This part number has been procured by the US Government within the last year, but shows no recent (last 90 days) procurement activity. There have been 2 contracts issued for this part number, with 2 awards given. There is minimal competition for this NSN. The US Government has awarded contracts to 2 different suppliers. The last contract numbers awarded were: SPE2DP24V2313, SPE2DP23P0841. The total value of the awarded contracts has been US$ 4,775.78.
There has been very little demand for this national stock number. The demand for this NSN originated from less than 5 countries. Based on a planned procurement review by the Primary Inventory Control Activity (PICA) on Dec 02, 2006, this NSN's acquisition method was noted as: Acquire directly from the actual manufacturer, whether or not the prime contractor is the actual manufacturer. This part is a commercial/non-developmental/off-the-shelf-item. Valid AMCs: 1, 2, 3, 4 and 5.
This NSN is assigned to Item Name Code (INC) 50275. This item does not have a nuclear hardened feature or any other critical feature such as tolerance, fit restriction or application. Information is in the Hazardous Materials Information Resource System (HMIRS). NSN 6505012656313 does not contain precious metals.
This NSN is associated to Schedule B 3006300000: opacifying preparations for x-ray examinations; diagnostic reageants designed to be administered to the patient. The Schedule B End Use is listed as pharmaceutical preparations. NAICS classification category 325412: pharmaceutical preparation manufacturing.
This information was last updated on Dec 01, 2024.